Kelun-Biotech Presents TROP2-ADC SKB264 Results at 2024 CSCO Congress in Xiamen
- The congress featured multiple studies on sac-TMT, a new therapeutic option for various cancers.
- Sac-TMT showed significant improvements in progression-free survival and overall response rates across different cancer types.
- Experts believe sac-TMT could become a new standard of care, addressing unmet needs in cancer treatment.
The 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting took place in Xiamen from September 25th to 29th, 2024, showcasing significant advancements in cancer treatment. Notably, the results of multiple studies on sac-TMT, a novel therapeutic option, were presented. In patients with metastatic triple-negative breast cancer (TNBC), sac-TMT demonstrated a median progression-free survival (PFS) of 8.3 months, significantly outperforming traditional chemotherapy. Additionally, the Phase II OptiTROP-Lung01 study reported promising outcomes for advanced non-small-cell lung cancer (NSCLC) patients treated with sac-TMT in combination with an anti-PD-L1 monoclonal antibody, achieving an overall response rate (ORR) of 48.6% in one cohort. Furthermore, the efficacy of sac-TMT was evaluated in recurrent or metastatic cervical cancer, showing a 57.9% ORR. In advanced endometrial and ovarian cancers, the treatment also yielded encouraging results, particularly in platinum-resistant patients. Experts emphasized the potential of sac-TMT to become a new standard of care in these cancer types, addressing unmet treatment needs and improving patient outcomes. The congress highlighted the importance of innovative drug development in oncology, with a focus on targeted therapies that can offer hope to patients facing challenging diagnoses.